Completed PHASE2 INTERVENTIONAL 1-arm NCT02447679

Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence

Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrent After Hepatectomy in High Risk Patients -A Phase II Study

Sponsor: Chang Gung Memorial Hospital

Conditions Adult Hepatocellular Carcinoma Adverse Reaction to Drug Recurrent Hepatocellular Carcinoma Vascular Endothelial Growth Factor Overexpression

Interventions tegafur-uracil thalidomine

Updated 7 times since 2017 Last updated: Feb 5, 2017 Started: Aug 31, 2010 Primary completion: Jan 31, 2017 Completion: Feb 2, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Adult Hepatocellular Carcinoma and Adverse Reaction to Drug and is currently completed. Chang Gung Memorial Hospital leads this study, which shows 7 recorded versions since 2010 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

Status: Recruiting → Completed
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE2

First recorded

Aug 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chang Gung Memorial Hospital

Data source: Chang Gung Memorial Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Taoyuan District, Taiwan